The 2026 Healthtech Messaging Index

Rank#29of 302

Clairity

clairity.com·scored November 1, 2026

71out of 100

27/38

Approaching

Close. The bones are good. A few targeted fixes on the weakest signals would push Clairity into magnetic territory.

ApproachingAI recommends them? No
Clairity homepage

The page we scored

The AI Recommendation Check

When we asked AI who to recommend for AI-powered breast cancer risk assessment from mammogram imaging, it named:

Buyer we put in the prompt: Women who have had a screening mammogram and want to understand their personal five-year breast cancer risk. Both the buyer and the category were inferred from Clairity’s homepage alone. The model had no web access.

iCADHologicVolpara HealthSolis MammographyGE HealthCareScreenpoint MedicalDensitasLunit

Clairity was not on the list.

A buyer who asked AI this question got 8 names and moved on. Clairity never came up.

We asked AI who it recommends for "Women who have had a screening mammogram and want to understand their personal five-year breast cancer risk" looking for "AI-powered breast cancer risk assessment from mammogram imaging". It named iCAD, Hologic, Volpara Health, Solis Mammography, GE HealthCare. You did not appear. AI can't recommend what it can't clearly understand.

Overall assessment

Clairity's biggest strength is its laser-clear, citation-ready hero statement ... 'first FDA-authorized AI platform' with a specific five-year risk mechanism ... which gives both human visitors and AI engines an immediately quotable, distinctive identity. The single biggest gap is zero acknowledgment of alternatives: no mention of genetic testing, competing risk models, or the cost of doing nothing, which leaves the page unable to close the skeptical buyer who is comparing options or wondering why this beats their current approach.

Signal by category

Narrative Clarity

8 signals

12/16

Trust Signal

4 signals

4/8

AI Signal

6 signals

10/12

Conversion Signal

1 signal

1/2
0

Weakest signal · fix this first

12Alternatives Acknowledged

“No mention of genetic testing, Tyrer-Cuzick, competing risk models, or 'do nothing' option anywhere on the page.”

The page never acknowledges that women could use genetic testing, other AI tools, or simply rely on standard mammography ... alternatives are completely absent.

All 19 signals, scored 0 to 2.

Narrative Clarity

8 signals

12/16
  • 01The 7-Second Test

    “Clairity Breast is the first FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer, using only her existing screening mammogram.”

    Within seconds above the fold, a stranger knows who it's for (women), what it does (predicts 5-year breast cancer risk), and the distinctive angle (uses existing mammogram, FDA-authorized AI) ... caveman-clear.

    2
  • 02Rebellion / Movement

    “For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI... can uncover hidden clues”

    There's an implicit rebellion against age-based, detection-only screening, but the page never names the enemy or status quo explicitly as something to push against ... it's framed as evolution, not revolt.

    1
  • 03Owned Language & Category

    “Clairity Breast™" and "the first FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer, using only her existing screening mammogram”

    The branded product name 'Clairity Breast™', the coined frame of 'image-based five-year risk estimate,' and FDA-authorization claim together give AI a citable, ownable identity distinct from generic 'AI mammography' language.

    2
  • 04ICP Clarity

    “Know your five-year breast cancer risk. It's already in your mammogram.”

    The ICP is unambiguous: women who have already had a mammogram and want to know their personal breast cancer risk ... no ambiguity about role, context, or use case.

    2
  • 05Problem Leadership

    “Peace of Mind Starts with Understanding Your Risk”

    The page opens on the emotional outcome (peace of mind) rather than naming the specific problem (women don't know their personal risk after a standard mammogram), so it leads with the aspiration rather than the problem in buyer language.

    1
  • 06Solution Clarity

    “Clairity Breast™ reads it to estimate your risk over the next five years.”

    A visitor can repeat exactly what the product does in one sentence after reading the hero ... reads your existing mammogram and gives you a 5-year breast cancer risk estimate.

    2
  • 07Cost of Inaction

    “Peace of Mind Starts with Understanding Your Risk”

    The page implies anxiety without knowing risk but never explicitly names the cost of inaction ... no missed diagnoses, no statistics about women who discover cancer too late, no named stakes for doing nothing.

    1
  • 08Promised Land

    “with your results reviewed by a licensed provider and next steps drawn from national guidelines”

    The promised land is gestured at (peace of mind, knowing your risk, getting next steps) but never painted vividly ... no specific 'after' scenario showing what a woman's life or healthcare decisions look like once she has her risk score.

    1

Trust Signal

4 signals

4/8
  • 09Proof & Evidence

    “predicts a woman's five-year future risk" and "first FDA-authorized”

    FDA authorization and the five-year risk window are concrete, but there are no outcome numbers ... no accuracy rates, no clinical validation statistics, no before/after deltas showing what knowing risk changes for patients.

    1
  • 10Social Proof

    “As Seen On" followed by logos of CNN, Oprah Daily, STAT, Women's Health, Fox News”

    Media logos are strong but there are no named patient testimonials, no clinician endorsements with names and titles, and no case studies ... press badges without human voices.

    1
  • 11Authority & Credibility

    “Dr. Connie Lehman" quoted with context: "advancements in AI and computer vision can uncover hidden clues in the mammograms ... invisible to the human eye”

    Founder is a named MD with a credible, specific scientific quote; NCCN guideline citations appear in news summaries; and FDA authorization demonstrates demonstrated authority, not claimed.

    2
  • 12Alternatives Acknowledgedweakest

    “No mention of genetic testing, Tyrer-Cuzick, competing risk models, or 'do nothing' option anywhere on the page.”

    The page never acknowledges that women could use genetic testing, other AI tools, or simply rely on standard mammography ... alternatives are completely absent.

    0

AI Signal

6 signals

10/12
  • 13Customer Focus

    “The mammogram you've already had can tell you more." and "Know your five-year breast cancer risk. It's already in your mammogram.”

    The page consistently addresses the woman as protagonist ... 'your mammogram,' 'your risk,' 'your results' ... the company's role is framed as the tool in her story, not the hero of its own.

    2
  • 14AI-Parmesan Index

    “the first FDA-authorized AI platform that predicts a woman's five-year future risk... using only her existing screening mammogram”

    The AI claim is specific and mechanistic ... FDA-authorized, image-based risk extraction, five-year prediction window ... not vague 'AI-powered' sprinkle; the mechanism is described concretely.

    2
  • 15LLM Quotability

    “Clairity Breast is the first FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer, using only her existing screening mammogram.”

    This sentence is clean, declarative, and citation-ready ... an LLM could lift it verbatim to describe the company accurately in any response about AI breast cancer risk tools.

    2
  • 16Copyright Freshness

    “News items dated 2026 (e.g., STAT article "2026/10/08") and image URLs showing 2026 upload dates throughout.”

    Multiple news articles carry 2026 dates and the Everlywell partnership is described as a current nationwide launch, giving AI engines strong recency signals.

    2
  • 17Entity Distinctiveness

    “first FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer, using only her existing screening mammogram”

    FDA-first status, the specific five-year risk frame from a single existing mammogram, Dr. Lehman as named founder-scientist, and the direct-to-consumer Everlywell channel combine into a profile no competitor can claim identically.

    2
  • 18AI Recommendation Check

    “AI's picks: iCAD, Hologic, Volpara Health, Solis Mammography, GE HealthCare, Screenpoint Medical. You were not named.”

    We asked AI who it recommends for "Women who have had a screening mammogram and want to understand their personal five-year breast cancer risk" looking for "AI-powered breast cancer risk assessment from mammogram imaging". It named iCAD, Hologic, Volpara Health, Solis Mammography, GE HealthCare. You did not appear. AI can't recommend what it can't clearly understand.

    0

Conversion Signal

1 signal

1/2
  • 19Path & CTA Clarity

    “Get started at Everlywell" and "How Clairity Breast works →" as two CTAs, but no numbered process steps shown.”

    There is a primary CTA (Get started at Everlywell) and a soft secondary (How Clairity Breast works), but there is no visible numbered process explaining what happens after you click ... the path is missing.

    1

Your move

Think Clairity’s score is wrong? Good. Let’s look at it together.

Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Clairity the AI recommendation, and what to write instead.

Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.

← Back to the full Healthtech index

We revamp websites that ChatGPT ignores.

See the 90-Day AI Website Rebuild →